November 10, 2025 — DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, announced that President and CEO Rick Pauls will participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025.
During the conference, Pauls will deliver a corporate presentation and engage in one-on-one investor meetings.
The Jefferies Global Healthcare Conference in London details are as follows (Greenwich Mean Time (GMT)):
Corporate Presentation:
Date: Thursday, November 20, 2025
Time: 10:00-10:25 AM
DiaMedica Therapeutics Inc. focuses on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. Their lead candidate, DM199, is a recombinant form of the KLK1 protein being clinically studied in the United States. Human-derived KLK1 is a therapeutic modality in China for treating acute ischemic stroke and other vascular diseases.
Source: DiaMedica Therapeutics Inc.
